Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2009

01-02-2009 | Preclinical Study

Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes

Authors: Toyone Kikumori, Takeshi Kobayashi, Masataka Sawaki, Tsuneo Imai

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

Background We have constructed anti-HER2 immunoliposomes containing magnetite nanoparticles (HML) that generate heat in an alternating magnetic field (AMF). The effective targeting and cytocidal abilities of HML have been achieved using cell culture models. This study aimed to investigate feasibility of this modality for breast cancer treatment using tumor-bearing mouse models. Material and methods The subcutaneous cancer nodules of BT474 (high HER2 expression) or SKOV3 (low HER2 expression) cells in nude mice were employed as models. HMLs were injected into these cancer nodules and were then exposed to an AMF for 30 min twice at 24 h intervals. Accumulation of magnetite and tumor growth rates were examined. Histological findings of the thermal effect were also examined. Results HMLs accumulated in only BT474 tumors. The tumor temperature increased to 45°C whereas the body temperature remained at around 38°C. Tumor regression was observed in the hyperthermic group and was sustained for 10 weeks after hyperthermia. Conclusion These results suggest that hyperthermia using HML is an effective and specific therapy for breast cancer overexpressing HER2. This therapy may provide an alternative way to treat recurrent cancer refractory to other modalities.
Literature
2.
go back to reference Moroz P, Jones SK, Gray BN (2002) Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 18:267–284PubMedCrossRef Moroz P, Jones SK, Gray BN (2002) Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 18:267–284PubMedCrossRef
3.
go back to reference Hand JW, Vernon CC, Prior MV, Gardner RA, Vargas HI, Block JB, Vogel CL, Fenn AJ, Kuehl GV, Doval M (1992) Early experience of a commercial scanned focused ultrasound hyperthermia system. Focused microwave phased array thermotherapy for primary breast cancer. Int J Hyperthermia 8:587–607PubMedCrossRef Hand JW, Vernon CC, Prior MV, Gardner RA, Vargas HI, Block JB, Vogel CL, Fenn AJ, Kuehl GV, Doval M (1992) Early experience of a commercial scanned focused ultrasound hyperthermia system. Focused microwave phased array thermotherapy for primary breast cancer. Int J Hyperthermia 8:587–607PubMedCrossRef
4.
go back to reference Gardner RA, Vargas HI, Block JB, Vogel CL, Fenn AJ, Kuehl GV, Doval M (2002) Focused microwave phased array thermotherapy for primary breast cancer. Ann Surg Oncol 9:326–332PubMedCrossRef Gardner RA, Vargas HI, Block JB, Vogel CL, Fenn AJ, Kuehl GV, Doval M (2002) Focused microwave phased array thermotherapy for primary breast cancer. Ann Surg Oncol 9:326–332PubMedCrossRef
5.
go back to reference Abe M, Hiraoka M, Takahashi M, Egawa S, Matsuda C, Onoyama Y, Morita K, Kakehi M, Sugahara T (1986) Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (Thermotron RF-8) in combination with radiation for cancer therapy. Cancer 58:1589–1595PubMedCrossRef Abe M, Hiraoka M, Takahashi M, Egawa S, Matsuda C, Onoyama Y, Morita K, Kakehi M, Sugahara T (1986) Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (Thermotron RF-8) in combination with radiation for cancer therapy. Cancer 58:1589–1595PubMedCrossRef
6.
go back to reference Oura S, Tamaki T, Hirai I, Yoshimasu T, Ohta F, Nakamura R, Okamura Y (2007) Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size. Breast Cancer 14:48–54PubMedCrossRef Oura S, Tamaki T, Hirai I, Yoshimasu T, Ohta F, Nakamura R, Okamura Y (2007) Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size. Breast Cancer 14:48–54PubMedCrossRef
7.
go back to reference Wu F, Wang ZB, Cao YD, Chen WZ, Bai J, Zou JZ, Zhu H (2003) A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer. Br J Cancer 89:2227–2233PubMedCrossRef Wu F, Wang ZB, Cao YD, Chen WZ, Bai J, Zou JZ, Zhu H (2003) A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer. Br J Cancer 89:2227–2233PubMedCrossRef
8.
go back to reference Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R (1993) Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 9:51–68PubMedCrossRef Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R (1993) Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 9:51–68PubMedCrossRef
9.
go back to reference Minamimura T, Sato H, Kasaoka S, Saito T, Ishizawa S, Takemori S, Tazawa K, Tsukada K (2000) Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats. Int J Oncol 16:1153–1158PubMed Minamimura T, Sato H, Kasaoka S, Saito T, Ishizawa S, Takemori S, Tazawa K, Tsukada K (2000) Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats. Int J Oncol 16:1153–1158PubMed
10.
go back to reference Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H, Kobayashi T (2003) Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J Biosci Bioeng 96:364–369PubMed Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H, Kobayashi T (2003) Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J Biosci Bioeng 96:364–369PubMed
11.
go back to reference Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T (1996) Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study. Jpn J Cancer Res 87:1179–1183PubMed Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T (1996) Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study. Jpn J Cancer Res 87:1179–1183PubMed
12.
go back to reference Suzuki M, Shinkai M, Honda H, Kobayashi T (2003) Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res 13:129–135PubMedCrossRef Suzuki M, Shinkai M, Honda H, Kobayashi T (2003) Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res 13:129–135PubMedCrossRef
13.
go back to reference Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T (1998) Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn J Cancer Res 89:463–469PubMed Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T (1998) Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn J Cancer Res 89:463–469PubMed
14.
go back to reference Hamaguchi S, Tohnai I, Ito A, Mitsudo K, Shigetomi T, Ito M, Honda H, Kobayashi T, Ueda M (2003) Selective hyperthermia using magnetoliposomes to target cervical lymph node metastasis in a rabbit tongue tumor model. Cancer Sci 94:834–839PubMedCrossRef Hamaguchi S, Tohnai I, Ito A, Mitsudo K, Shigetomi T, Ito M, Honda H, Kobayashi T, Ueda M (2003) Selective hyperthermia using magnetoliposomes to target cervical lymph node metastasis in a rabbit tongue tumor model. Cancer Sci 94:834–839PubMedCrossRef
15.
go back to reference Goldenberg MM (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21:309–318PubMedCrossRef Goldenberg MM (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21:309–318PubMedCrossRef
16.
go back to reference Hortobagyi GN (2001) Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 28:43–47PubMedCrossRef Hortobagyi GN (2001) Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 28:43–47PubMedCrossRef
17.
go back to reference Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, Watanabe Y, Kobayashi T (2004) Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett 212:167–175PubMedCrossRef Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, Watanabe Y, Kobayashi T (2004) Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett 212:167–175PubMedCrossRef
18.
go back to reference Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83:249–289PubMedCrossRef Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83:249–289PubMedCrossRef
19.
go back to reference Shinkai M, Suzuki M, Iijima S, Kobayashi T (1995) Antibody-conjugated magnetoliposomes for targeting cancer cells and their application in hyperthermia. Biotechnol Appl Biochem 21(Pt 2):125–137PubMed Shinkai M, Suzuki M, Iijima S, Kobayashi T (1995) Antibody-conjugated magnetoliposomes for targeting cancer cells and their application in hyperthermia. Biotechnol Appl Biochem 21(Pt 2):125–137PubMed
20.
go back to reference Ito A, Honda H, Kobayashi T (2006) Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expression. Cancer Immunol Immunother 55:320–328PubMedCrossRef Ito A, Honda H, Kobayashi T (2006) Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expression. Cancer Immunol Immunother 55:320–328PubMedCrossRef
21.
go back to reference Kawai N, Ito A, Nakahara Y, Futakuchi M, Shirai T, Honda H, Kobayashi T, Kohri K (2005) Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. Prostate 64:373–381PubMedCrossRef Kawai N, Ito A, Nakahara Y, Futakuchi M, Shirai T, Honda H, Kobayashi T, Kohri K (2005) Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. Prostate 64:373–381PubMedCrossRef
22.
go back to reference Kawai N, Ito A, Nakahara Y, Honda H, Kobayashi T, Futakuchi M, Shirai T, Tozawa K, Kohri K (2006) Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core. Prostate 66:718–727PubMedCrossRef Kawai N, Ito A, Nakahara Y, Honda H, Kobayashi T, Futakuchi M, Shirai T, Tozawa K, Kohri K (2006) Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core. Prostate 66:718–727PubMedCrossRef
Metadata
Title
Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes
Authors
Toyone Kikumori
Takeshi Kobayashi
Masataka Sawaki
Tsuneo Imai
Publication date
01-02-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9948-x

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine